There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCA Healthcare (HCA – Research Report) and NRX Pharmaceuticals (NRXP – Research Report) with bullish sentiments.
HCA Healthcare (HCA)
Goldman Sachs analyst Jamie Perse maintained a Buy rating on HCA Healthcare today and set a price target of $329.00. The company’s shares closed last Tuesday at $220.66.
According to TipRanks.com, Perse is a 2-star analyst with an average return of
Currently, the analyst consensus on HCA Healthcare is a Strong Buy with an average price target of $315.31, a 44.1% upside from current levels. In a report issued on October 10, Bernstein also maintained a Buy rating on the stock with a $294.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
NRX Pharmaceuticals (NRXP)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on NRX Pharmaceuticals today and set a price target of $2.00. The company’s shares closed last Tuesday at $0.27, close to its 52-week low of $0.22.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Currently, the analyst consensus on NRX Pharmaceuticals is a Moderate Buy with an average price target of $3.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HCA:
